Literature DB >> 17294670

Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression.

Akira Yamada1, Kazuhiro Oguchi, Mana Fukushima, Yutaka Imai, Masumi Kadoya.   

Abstract

OBJECTIVE: Variable uptake of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has been noticed in positron emission tomography (PET) studies of gastric carcinoma patients, with low uptake occurring especially in some particular histological subtypes and early carcinomas. But this phenomenon has not been adequately explained. The aim of the present study is to clarify FDG uptake in gastric carcinomas especially focusing on histological subtypes, the depth of tumor invasion, and glucose transporter-1 (GLUT-1) expression which is considered to be one of the major factors for higher FDG uptake in human malignant tumors.
METHODS: FDG-PET was performed on 35 preoperative patients with gastric carcinoma. Forty macroscopically distinguishable lesions on a surgical specimen were histologically classified into two subtypes: Cohesive type (papillary adenocarcinoma, tubular adenocarcinoma, and solid type poorly differentiated adenocarcinoma) or Noncohesive type (signet-ring cell carcinoma and non-solid type poorly differentiated carcinoma). GLUT-1 expression was immunohistochemically determined. Histological parameters (GLUT-1 expression, histological subtypes, the depth of invasion, lymphatic permeation, venous invasion and tumor size) were evaluated, and factors for FDG uptake (detectability and the degree) and GLUT-1 overexpression were determined by multiple regression analysis.
RESULTS: Nineteen of 40 gastric carcinomas showed detectable FDG uptake (48%), multiple regression analysis revealed that both the depth of invasion and histological subtypes are independent factors that influence the detectable FDG uptake in gastric carcinoma (R2 = 0.66). GLUT-1 expression was seen from an early cancer stage and the cohesive type was an independent factor influencing the overexpression of GLUT-1 (R2 = 0.66). GLUT-1 expression was the most influential factor for the degree of FDG uptake in gastric carcinoma (R2 = 0.68).
CONCLUSIONS: This study provided important information on the clinical application of FDG-PET in gastric carcinoma that early or non-cohesive gastric carcinoma may show lower FDG uptake. Therefore, the usefulness of FDG-PET for the detection of gastric carcinoma is limited. But there is a possibility that FDG uptake associated with GLUT-1 expression may serve as a prognostic factor of gastric carcinoma representing tumor metabolism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17294670     DOI: 10.1007/bf02984657

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  37 in total

1.  Primary signet ring cell carcinoma of uterine cervix and related disease: two case reports and a review.

Authors:  Kohei Hamada; Tsukasa Baba; Aya Takaori; Ryusuke Murakami; Akihito Horie; Kaoru Abiko; Sachiko Minamiguchi; Masaki Mandai
Journal:  Int Cancer Conf J       Date:  2019-05-17

2.  Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.

Authors:  Nikolaos Charalampakis; Lianchun Xiao; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Venkatram Planjery; Jane E Rogers; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani
Journal:  Oncology       Date:  2015-09-23       Impact factor: 2.935

Review 3.  Glucose metabolism in gastric cancer: The cutting-edge.

Authors:  Lian-Wen Yuan; Hiroharu Yamashita; Yasuyuki Seto
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 4.  Diagnosis and evaluation of gastric cancer by positron emission tomography.

Authors:  Chen-Xi Wu; Zhao-Hui Zhu
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

5.  Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT.

Authors:  Bowen Shi; Huimin Lin; Miao Zhang; Wei Lu; Ying Qu; Huan Zhang
Journal:  J Vis Exp       Date:  2018-01-22       Impact factor: 1.355

6.  Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yoshitaka Uchida; Katsuhiro Uchiyama; Satomi Tanaka; Takafumi Sunaoshi; Daisuke Kano; Eriko Sugiyama; Misaki Shite; Ryouta Haga; Yoshiya Fukamizu; Toshiyuki Fujita; Satoshi Kagayama; Rumiko Hasegawa; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

7.  Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET.

Authors:  Reiko Kameyama; Yuka Yamamoto; Kunihiko Izuishi; Ryusuke Takebayashi; Masanobu Hagiike; Makiko Murota; Masato Kaji; Reiji Haba; Yoshihiro Nishiyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

8.  The early use of PET-CT alters the management of patients with esophageal cancer.

Authors:  R N Williams; S S Ubhi; C D Sutton; A L Thomas; J J Entwisle; D J Bowrey
Journal:  J Gastrointest Surg       Date:  2009-01-28       Impact factor: 3.452

9.  Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.

Authors:  Long Sun; Xin-Hui Su; Yong-Song Guan; Wei-Ming Pan; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

10.  Assessment of (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer.

Authors:  Tsutomu Namikawa; Takehiro Okabayshi; Munenobu Nogami; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Int J Clin Oncol       Date:  2013-07-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.